Anne Mosiman, NP
Nurse Practitioner · Corpus Christi, TXNPI 1861509168
Payments from drug & device makers
Across 317 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- AstraZeneca$515
- Amarin Pharma, Inc.$372
- Merck$332
- Dexcom, Inc.$315
- plus $2K from 20 others
What the payments were for
- Food & beverage$7,08798%
- Education$1182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 81 | $1,757 |
| Lilly USA, LLC | 84 | $1,626 |
| AstraZeneca | 7 | $515 |
| Amarin Pharma, Inc. | 28 | $372 |
| Merck | 22 | $332 |
| Dexcom, Inc. | 14 | $315 |
| GSK | 18 | $298 |
| Corcept Therapeutics | 3 | $290 |
| AbbVie | 15 | $270 |
| Esperion Therapeutics, Inc. | 3 | $239 |
| Bayer | 11 | $174 |
| Amgen | 4 | $162 |
| Biohaven Pharmaceuticals, Inc. | 2 | $141 |
| Si-bone, Inc. | 1 | $131 |
| Johnson & Johnson | 1 | $124 |
| Sanofi-aventis U.S. LLC | 3 | $114 |
| Exact Sciences | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Abbott | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Pfizer | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$329
- Ozempic$241
- NEXLIZET$225
- NEXLETOL$225
- ZEPBOUND$225
- Korlym$217
- iFuse Implant$131
- DEXCOM G6 TRANSMITTER$126
- NURTEC ODT$125
- KISUNLA$125
- XARELTO$124
- MOUNJARO$122
- EVENITY$118
- Saxenda$111
- RYBELSUS$108
How this compares
$7,204 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 95 | $114,674 |
| JardianceEmpagliflozin | 81 | $101,255 |
| OzempicSemaglutide | 56 | $60,887 |
| TrulicityDulaglutide | 32 | $55,926 |
| EliquisApixaban | 60 | $49,175 |
| RybelsusSemaglutide | 15 | $31,079 |
| FarxigaDapagliflozin Propanediol | 21 | $28,914 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $21,623 |
| XareltoRivaroxaban | 23 | $18,261 |
| LinzessLinaclotide | 12 | $12,693 |
| JanuviaSitagliptin Phosphate | 13 | $8,223 |
| BelsomraSuvorexant | 19 | $8,089 |
| MyrbetriqMirabegron | 12 | $7,786 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $6,048 |
| Levothyroxine Sodium | 495 | $4,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,626 | $170,600127 claims |
| Novo NordiskOzempic, Rybelsus | $1,757 | $91,96671 claims |
| PfizerEliquis | $30 | $49,17560 claims |
| AstraZenecaFarxiga | $515 | $28,91421 claims |
| Johnson & JohnsonXarelto | $124 | $18,26123 claims |
| MerckJanuvia, Belsomra | $332 | $16,31232 claims |
| AbbVieLinzess, Synthroid | $270 | $14,43732 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $7,78612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Corpus Christi
- Roxana ReynaCorpus Christi$32K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Kelly BrassilHouston$194K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Monica WhiteLongview$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.